Patents Represented by Attorney Charles W. Ashbrook
  • Patent number: 7259241
    Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: August 21, 2007
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Kim J. Stutzman-Engwall, Hamish McArthur
  • Patent number: 7250518
    Abstract: Compounds of the formula: useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc.
    Inventors: Thomas V. Magee, Anthony Marfat, Robert J. Chambers
  • Patent number: 7238723
    Abstract: The present invention provides eletriptan hydrobromide monohydrate of the formula (I): together with processes for preparing, uses of, and compositions containing, said monohydrate.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: July 3, 2007
    Assignee: Pfizer Inc.
    Inventors: Christopher Ian Dallman, Ronald James Ogilvie
  • Patent number: 7214712
    Abstract: Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein: R1, R2, and R3 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; each R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.
    Type: Grant
    Filed: September 29, 2005
    Date of Patent: May 8, 2007
    Assignee: Warner-Lambert Company
    Inventors: Nicole Chantel Barvian, David Thomas Connor, Richard Dennis Dyer, Adam Richard Johnson, William Chester Patt
  • Patent number: 7214676
    Abstract: The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III) in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 8, 2007
    Assignee: Warner-Lambert Company LLC
    Inventors: Patrick Bernardelli, Pierre Ducrot, Edwige Lorthiois, Febrice Vergne
  • Patent number: 7214824
    Abstract: This invention provides a compound of the formula (I): wherein R1 represents a (C1–C6)alkyl group; R2 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1–C6)alkyl group or a (C1–C6)alkoxy group; R3, R4, R5 and R6 each independently represents a hydrogen atom, a (C1–C6)alkyl, or a halogen atom; R7 represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1–C6)alkyl group optionally substituted with a piperidino group, a (C1–C6)alkoxy group optionally substituted with a 3–7 membered cycloalkyl ring, a hydroxy(C1–C6)alkoxy group, a (C1–C6)alkoxy-(C1–C6)alkyl group, a (C1–C6)alkoxy-(C1–C6)alkoxy group, a halo (C1–C6)alkyl group, a (C1–C6)alkylthio group, a (C1–C6)alkylsulfinyl group or a (C1–C6)alkylsulfonyl group; R8 represents a (C1–C6)alkyl group, a halo(C1–C6)alkyl group, a (C1–C6)alkoxy group, a hydroxy(C1–C6)alkoxy group, a (C1–C6)alkoxy-(C1–C6)alkyl group or a (C1–C6)alkoxy-(C1–C6)alkoxy group; or R7 and R8, when adjacent to each other, taken together with the carbon atoms to whic
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: May 8, 2007
    Assignee: Pfizer Inc.
    Inventors: Tadashi Inoue, Satoshi Nagayama, Kazunari Nakao
  • Patent number: 7193056
    Abstract: The present invention relates to a process for purifying a hydrophobic or amphiphilic compound, by first mixing a starting material containing the hydrophobic or amphiphilic compound with a first polymeric material, water and at least one of a second polymeric material and a surfactant, wherein the first polymeric material and the second polymeric material and/or surfactant are immiscible in the resulting primary aqueous solution. The process further comprises maintaining the primary aqueous solution for a period of time sufficient for essentially separating the phases formed, and then removing the phase containing the main portion of the hydrophobic or amphiphilic compound and the second polymeric material and/or surfactant. The second polymeric material and/or surfactant are separated from the hydrophobic or amphiphilic compound, and subsequently recycled to the initial mixing step.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: March 20, 2007
    Assignee: Pharmacia & UpJohn AB
    Inventors: Hans Ageland, Lena Nyström, Josefine Persson, Folke Tjerneld
  • Patent number: 7186742
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: March 6, 2007
    Assignee: Pfizer Inc
    Inventors: Mark A Dombroski, Allen J. Duplantier, Chakrapani Subramanyam
  • Patent number: 7179822
    Abstract: This invention provides compounds defined by Formula I and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of treating osteo- and rheumatoid arthritis.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: February 20, 2007
    Assignees: Warner-Lambert Company, Warner-Lambert Company LLC
    Inventors: Amy Mae Bunker, Mark Anthony Morris, Patrick Michael O'Brien, Michael William Wilson
  • Patent number: 7179934
    Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. Also disclosed are methods of making the ?-amino acids.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: February 20, 2007
    Assignee: Warner-Lambert Company LLC
    Inventors: Peter Garth Blazecka, Joseph Richard Bozelak, Norman Lloyd Colbry, Timothy Thomas Curran, Annise Paige Goodman, Kevin E. Henegar, Garrett Hoge, Paul D. Johnson, Augustine Tobi Osuma, Mark Stephen Plummer, Jacob Bradley Schwarz, Derek Clinton Vrieze, Ji Zhang
  • Patent number: 7176202
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1–R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: February 13, 2007
    Assignee: Pfizer Inc.
    Inventors: Mark A. Dombroski, Allen J. Duplantier
  • Patent number: 7173052
    Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: February 6, 2007
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Stuart E. Bradley, Eric W. Collington, Matthew C. Fyfe, Martin J. Procter, Colin P. Sambrook Smith
  • Patent number: 7164030
    Abstract: The present invention provides an improved process for the preparation of ?-polymorphic eletriptan hydrobromide.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: January 16, 2007
    Assignee: Pfizer Inc.
    Inventors: Patrick Joseph Furlong, Cornelius Joseph Kelly, Ronald James Ogilvie, Vincent Ryan
  • Patent number: 7148234
    Abstract: Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: December 12, 2006
    Assignee: Pfizer Inc.
    Inventors: Masato Shimojo, Kana Taniguchi
  • Patent number: 7141586
    Abstract: This invention relates to nicotinamide derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing, and the uses of such derivatives: wherein each substituent is defined herein.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: November 28, 2006
    Assignee: Pfizer Inc.
    Inventors: Simon Bailey, Christopher Gordon Barber, Paul Alan Glossop, Donald Stuart Middleton
  • Patent number: 7141608
    Abstract: Alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt are crystalline and have the formula wherein R1 is H or lower alkyl, and x is a number from 0 to 10, and are useful for treating dyslipidemia.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: November 28, 2006
    Assignee: Warmer-Lambert Company LLC
    Inventors: Howard Yoshihisa Ando, Donald Eugene Butler, Gary Jay Dozeman
  • Patent number: 7141580
    Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5–12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5–6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5–12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl; R5 is H, C1-4 alkyl, etc.; Q2 is a 5–12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: November 28, 2006
    Assignee: Pfizer Inc.
    Inventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
  • Patent number: 7138542
    Abstract: The invention relates to a method of treating tinnitus by administering an alpha2delta ligand such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: November 21, 2006
    Assignee: Warner Lambert Company
    Inventors: David James Dooley, David Juergen Wustrow
  • Patent number: 7132435
    Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, X, Y, Z and R2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: November 7, 2006
    Assignee: Pfizer Inc.
    Inventors: Mya Coral Helen Smith, Christine Anne Louise Watson
  • Patent number: 7132549
    Abstract: The present invention provides an improved process for the preparation of a polymorph of eletriptan hemisulphate.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: November 7, 2006
    Assignee: Pfizer Inc.
    Inventors: Julian Aranda-Martinez, Catherine Dunne, Juergen Friedrich Kleinschroth, Julie Ann MacRae, Richard Anthony Storey, Ellen Johanna Weilbacher